spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  rosiglitazone 

 HSMN NewsFeed - 18 Apr 2017
Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
Biopharmaceuticals Gastroenterology Surgery Personnel
 HSMN NewsFeed - 23 Sep 2010
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 24 Feb 2010
GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Jul 2008
FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 8 Apr 2008
GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2007
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 14 Nov 2007
GSK Revises US Labeling for Avandia(R)
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 27 Sep 2007
Teva Announces Settlement of Generic Avandia(R), Avandamet(R), and Avandaryl(R) Litigation with GlaxoSmithKline
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 19 Sep 2007
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
GlaxoSmithKline Responds to JAMA Articles
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 14 Aug 2007
GlaxoSmithKline Updates Prescribing Information for Avandia
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 31 Jul 2007
Endocrinologists Welcome FDA Avandia Recommendation
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 31 Jul 2007
FDA Advisory Panel Votes 22 to 1 for Avandia(R) to Remain Available to Patients in the US
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 30 Jul 2007
GlaxoSmithKline Presents Avandia Data To FDA
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 11 Jul 2007
Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jun 2007
New Data Show Patients Treated With Avandia(R) (Rosiglitazone Maleate) Incurred Lower Medical Costs and Used Fewer Healthcare Resources When Compared to Patients Treated With Sulphonylureas
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Jun 2007
Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus(R) Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Jun 2007
Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Jun 2007
Newly Published Data From Large Study Support Cardiovascular Safety of Avandia (rosiglitazone maleate)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 30 May 2007
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 May 2007
Statement From the American Association of Clinical Endocrinologists Regarding The New England Journal of Medicine Article, "Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes"
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 21 May 2007
GlaxoSmithKline Responds to NEJM Article on Avandia
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 17 Apr 2007
GTx Announces Ostarine(TM) Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 4 Dec 2006
Landmark Study Shows Avandia(R) (rosiglitazone maleate) Is More Effective Than Metformin or a Sulfonylurea in Long-Term Blood Sugar Control in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 11 Oct 2006
Novartis Launches 'GALIANT' Study Comparing the Investigational Drug Galvus(R) and a Leading Class of Oral Anti-Diabetic Medicines
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 15 Sep 2006
King Pharmaceuticals Reports DREAM Data on Ramipril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Sep 2006
Avandia(R) (rosiglitazone maleate) Reduced Risk of Progression From Pre-Diabetes To Type 2 Diabetes by 62 Percent in Largest Completed Diabetes Prevention Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 11 Jul 2006
GlaxoSmithKline Announces FDA Approval and the Launch of Avandamet(R) (Rosiglitazone Maleate and Metformin HCl) as Initial Therapy in the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
rosiglitazone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.